echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Clinical approval for Omicron Aibo Biotech's new coronavirus mRNA vaccine in the United Arab Emirates

    Clinical approval for Omicron Aibo Biotech's new coronavirus mRNA vaccine in the United Arab Emirates

    • Last Update: 2022-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the mRNA vaccine of the new coronavirus of Aibo Bio-Omicron variant was approved for clinical use in the United Arab Emirates
    .
    For the Austrian strain, Aibo Biosciences will start the development of mRNA vaccines at the end of November 2021, and it will take only 32 days to complete the design of mRNA sequences to obtain preliminary immunogenicity data in mice

    .
    In addition to the UAE, Expro is currently actively communicating with regulatory agencies in many countries around the world, including China, with a view to conducting corresponding clinical trials as soon as possible in accordance with regulatory requirements

    .
    In June 2020, the new coronavirus mRNA vaccine jointly developed by Aibo Bio, the Academy of Military Medical Sciences of the Academy of Military Sciences and Watson Bio was officially approved by the State Drug Administration for clinical trials, becoming the first mRNA approved for clinical trials in China vaccine

    .
    The vaccine is currently in Phase III clinical trials

    .
    The company has obtained the "Drug Production License" for the new crown mRNA vaccine in November 2021

    .

    Source: 21st Century Business Herald

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.